EP3752509A1 - Flavocillin: a new penicillin derivative - Google Patents
Flavocillin: a new penicillin derivativeInfo
- Publication number
- EP3752509A1 EP3752509A1 EP18713342.6A EP18713342A EP3752509A1 EP 3752509 A1 EP3752509 A1 EP 3752509A1 EP 18713342 A EP18713342 A EP 18713342A EP 3752509 A1 EP3752509 A1 EP 3752509A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- flavocilin
- flavonoid
- methods
- antibiotic
- penicilin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002960 penicillins Chemical class 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 230000037361 pathway Effects 0.000 claims abstract 2
- 229930003935 flavonoid Natural products 0.000 claims description 10
- 150000002215 flavonoids Chemical class 0.000 claims description 10
- 235000017173 flavonoids Nutrition 0.000 claims description 10
- 235000013616 tea Nutrition 0.000 claims description 4
- 241001122767 Theaceae Species 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims 1
- 230000009471 action Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 229930003944 flavone Natural products 0.000 claims 1
- 150000002212 flavone derivatives Chemical class 0.000 claims 1
- 235000011949 flavones Nutrition 0.000 claims 1
- 235000015092 herbal tea Nutrition 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000002715 modification method Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 235000011149 sulphuric acid Nutrition 0.000 claims 1
- 239000001117 sulphuric acid Substances 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 238000010189 synthetic method Methods 0.000 claims 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical group O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 241000241413 Propolis Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000264877 Hippospongia communis Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/74—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with carbocyclic rings directly attached to the carboxamido radical
Definitions
- Flavocillin A new novel antibitoic that the bacteria will never develop resistance
- Flavocilin For obtaining Flavocilin, the R group must be replaced with a basic flavonoid and there may be more ways than what is being described at the claims part of this invention. Fortunately, obtaining Flavocilin is a simple Chemical process as a conclusion drawn from its theoretical studies.
- Flavonoids are very useful antimicrobial compounds of herbal origin found naturally in certain teas and Propolis, a solution available to be used in Medicine which is what the honey bee uses to prevent his honey comb from microbes while producing honey.
- Propolis alone readily available from Holland and Barret Stores, is full of flavonoids and as such it is effective in treating certain respiratory tract infections and also persistent flue, as a natural remedy.
- Flavocilin can easily be obtained with simple reactions.
- Flavocilin can always be used as a final choice of antibiotic where patient responds to no other antibiotic treatment, and it is impossible not to respond to Flavocilin due to dual mechanism of action stated previously.
- Flavocilin will be the solution for the problem of the century, antibiotic resistance, even after centuries due to penicilin-flavonoid dual strength effects.
- Flavocilin needs to be tested against virus effectiveness also. Due to its flavonoid group and Penicilin group, it can have a wider range of Pharmacological use and tests can determine if it will cancel, prevent, treat or minimise viral resistance, and if so, to what levels? The likelihood of finding out that it is very powerful against virus also will add benefit to its revolutionary importance and non-competitive unique advantages.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
This invention is about the discovery of a new novel compound as an antibiotic to stop this potential resistance problem completely. With Organic Chemistry studies and methods and other modified antibiotics, adding a flavonoid group to varibale side R instead which will result in flavocilin formation will be the most effective and revolutionary antibiotic that the bacteria will never be able to resist. Evidentful pathways have been conculded stating that the Flavocilin use in Medicine for heavy infectious conditions or where no other antibiotic works will outweigh all its risks.
Description
Flavocillin: A new novel antibitoic that the bacteria will never develop resistance
Resistance to antibiotics is a complicated growing problem of the centruy. Presently, this problem has been so much getting the attention of Medical Research Institutions and health organizations that there is a huge alert in preventing antibiotic resistance. There are reports estimating that many people will die in 2050’s due to antibiotics not working anymore as a result of this resistance. The simplest evidence that Flavocillin will be an effective antibiotic is that many stronger antibiotics were obtained by modifying the variable group (R) in Penicilin Chemical structure.
For obtaining Flavocilin, the R group must be replaced with a basic flavonoid and there may be more ways than what is being described at the claims part of this invention. Fortunately, obtaining Flavocilin is a simple Chemical process as a conclusion drawn from its theoretical studies.
Flavonoids are very useful antimicrobial compounds of herbal origin found naturally in certain teas and Propolis, a solution available to be used in Medicine which is what the honey bee uses to prevent his honey comb from microbes while producing honey. Propolis alone, readily available from Holland and Barret Stores, is full of flavonoids and as such it is effective in treating certain respiratory tract infections and also persistent flue, as a natural remedy.
In drug discovery and development process, adding effective Bioactive compounds to R groups of already active Chemical compounds as drug molecules is important to obtain much stronger effects than that of those drug molecules being used alone in treatment.
Possible advantages and disadvantages of Flavocilin as a new drug
development
Advantages:
Due to dual destructive mechanism effects (Cell wall inhibition and microbial destruction by bioactive flavonoid group as R (variable) group of Penicillin), the bacteria will never have the ability to resist to Flavocilin and therefore it will be the most powerful antibiotic via this defined dual strength of bioactivity.
As suggested in Chemical synthesis route part of claims, Flavocilin can easily be obtained with simple reactions.
Non-competitive advantage for the developer industry or for the drug company as a company holding the license rights of production during 20 years of patent protection.
Flavocilin can always be used as a final choice of antibiotic where patient responds to no other antibiotic treatment, and it is impossible not to respond to Flavocilin due to dual mechanism of action stated previously.
Flavocilin will be the solution for the problem of the century, antibiotic resistance, even after centuries due to penicilin-flavonoid dual strength effects.
Flavocilin needs to be tested against virus effectiveness also. Due to its flavonoid group and Penicilin group, it can have a wider range of Pharmacological use and tests can determine if it will cancel, prevent, treat or minimise viral resistance, and if so, to what levels? The likelihood of finding out that it is very powerful against virus also will add benefit to its revolutionary importance and non-competitive unique advantages.
Disadvantages:
Stronger effects may bring further side effects (but as flavonids are naturally found in tea and little or moderate tea consumption is known to have no noticable toxic effects, this risk is not likely).
Clinical testing to fully determine Pharmacological effects have not yet been determined.
Easy making of flavocilin can result in easy illegal flavocilin production (This is a probability but yet it is not very likely as per strict regulationbs and restrictions of patent law and also because a laboratory is still needed for its production although the method is not quite complicated.
References:
1. Nature volume 179, pages 892-893 (04 May 1957) doi: 10.1038/179892a0
2. J. Am. Chem. Soc. , 1957, 79 (5), pp 1262-1263. DOI:
10.1021/ja01562a063
3. Protein Sci. 2009 Mar; 18(3): 595-605. doi: 10.1002/pro.67 PMCID:
PMC2760365
Claims
1. This invention is about the discovery of a new novel antibiotic of maximum effectiveness that can ever be obtained by simpler than usual Chemical synthesis and modification methods, namely“Flavocilin”.
2. Flavocilin will overcome all the possible and potential antibiotic resistance problems and mechanisms as per stated mechnaisms of action and its unqiue and basic structure will be the strongest antibiotic ever used in Medicine, according to claim 1.
3. Flavocilin will consist of a flavonoid as R group attached to basic penicilin structure, according to claim 2.
4. Flavocilin can simply be obtained/synthesized in a Chemistry laboratory as following moderate detail synthesis methods (Other synthetic methods can also be developed besides this and grams and scales yet need to be determined by expert Organic/synthetic Chemists in field): Any basic flavonoid or a flavone solution is firstly extracted from a herbal tea by using any one of dichloromethane, diethyl ether, chloroform or ethyl acetate as a solvent. There are more than one way of extraction and many of these methods are available from many different public resources. The flavonoid extract is then isolated from the rest of the tea and H2S04 is added to the isolated flavonoid solution to produce lone paired Oxygens (as Flavonoids contain Oxygen around Cyclic carbons). The solution is then reacted with a readily available penicilin powder so that the formed lone pairs around Oxygen(s) in flavonoid attack the carbon attached to NH, O and R groups of Penicilin. This will result in double bond brokage and newly formed bond with the flavonoid due to an SN reaction. Since Penicilin contains Sulphur atom and methyls, an acid or other acidic compounds such as Sulphuric acid is likely to be resulted from this reaction, but such formed acids can easily be removed with the addition of a base to the solution resulting in salt formation that can be extracted and isolated later on so that it is gotten rid as it is unwanted. Finally, identification methods such as High Performance Liquid Chromatography (HPLC) and Carbon NMR must be used to analyze the solution to ensure the finally obtained sample contains Flavocilin and to ensure its structure represents the Flavocilin structure as identified in figure 2 of drwaings part of the invention. Once this is ensured, the very final step of the process is to purify the sample with
purification methods to obtain 99% Flavocilin. Alternative synthetic routes or pathways at any stage is also possible.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2018/050851 WO2019155266A1 (en) | 2018-02-12 | 2018-02-12 | Flavocillin: a new novel antibitoic that the bacteria will never develop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3752509A1 true EP3752509A1 (en) | 2020-12-23 |
Family
ID=61768349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18713342.6A Pending EP3752509A1 (en) | 2018-02-12 | 2018-02-12 | Flavocillin: a new penicillin derivative |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3752509A1 (en) |
| WO (1) | WO2019155266A1 (en) |
-
2018
- 2018-02-12 EP EP18713342.6A patent/EP3752509A1/en active Pending
- 2018-02-12 WO PCT/IB2018/050851 patent/WO2019155266A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019155266A1 (en) | 2019-08-15 |
| WO2019155266A8 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ebiloma et al. | Bioassay-guided isolation of active principles from Nigerian medicinal plants identifies new trypanocides with low toxicity and no cross-resistance to diamidines and arsenicals | |
| CN105503531A (en) | Extract of fungus culture as well as preparation method and application of extract | |
| EP3752509A1 (en) | Flavocillin: a new penicillin derivative | |
| CN104224863B (en) | Lysimachia herb total flavone is preparing the application in treating antihyperuricemic disease drug | |
| CN102276632A (en) | Praziquantel derivative as well as preparation and application thereof | |
| Parmar et al. | Mast cell membrane stabilization and anti-histaminic actions possible mechanism of action of anti-inflammatory action of Murraya koenigii | |
| RU2572231C1 (en) | Method for producing antibacterial preparation of manna gum leaves | |
| CN107212029A (en) | Herba Agrimoniae extract is being prepared for removing the application in tomato plant in the medicine of plant virus | |
| RU2565450C1 (en) | Cationic purpurinimide having antibacterial activity and using same for photodynamic inactivation of bacterial biofilms | |
| RU2519666C1 (en) | Agent showing anti-opisthorchiasis action, and method for preparing it | |
| CN101385796B (en) | New use of a formulation in improving cognition dysfunction and preventing and treating senile dementia | |
| CN109496211B (en) | Piperazine derivative for resisting candida albicans as well as preparation method and application thereof | |
| CN107304214B (en) | Water-soluble ginkgolide B carbamate derivative and preparation method and application thereof | |
| RU2615356C1 (en) | Method for lutenurinum preparation manufacture from yellow water-lily (nuphar lutea (l) smith) | |
| Marks | Sea Lavender Endophyte's | |
| Okere et al. | Antibacterial and antifungal activity of methanolic leaf extract of Allium sativum on selected pathogenic strains | |
| RU2664453C1 (en) | Derivative of 3-hydroxypyridine with anxiolytic and nootropic effect | |
| Devi et al. | Organic solvents can influence acetylcholine neurotransmission in Caenorhabditis elegans | |
| Banerjee et al. | A STUDY TO EVALUATE THERAPEUTIC POTENTIAL OF POGOSTEMON CABLIN OIL AGAINST EXPERIMENTALLY INDUCED ALZHEIMER’S DISEASE IN MICE | |
| RU2471787C1 (en) | Dimephosphone nicotinoylhydrazone possessing anti-tuberculosis activity | |
| Innocent et al. | SYSTEMATIC ANALYSIS OF ANTIBACTERIAL ACTIVITY OF PLANT EXTRACTS FROM PHYTOLACCA DODECANDRA AND DATURA STRAMONIUM | |
| Ganaie | Fungal Diseases of Animals: Symptoms and Their Cure by Natural Products | |
| WO2023237795A1 (en) | Use of the (+)-elatol compound for treating or preventing a naegleria fowleri infection | |
| CN102091105B (en) | New application of field pennycress and preparation thereof | |
| Kumar et al. | Screening of Various Plant Extracts for Antimicrobial Activity against Multi Drug Resistant P. aeruginosa, S. aureus and B. subtillis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200828 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20220530 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CERKEZ, GUENAY Owner name: PEHLIVAN, MUSTAFA |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CERKEZ, GUENAY Inventor name: PEHLIVAN, MUSTAFA |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CERKEZ, GUENAY Inventor name: PEHLIVAN, MUSTAFA |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PEHLIVAN, MUSTAFA |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |